A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer

Robert W. Holloway, Premal H. Thaker, Alberto A. Mendivil, Sarfraz Ahmad, Ahmed Al‐Niaimi, James Barter, Tiffany L. Beck, Setsuko K. Chambers, Robert L. Coleman, Sarah Crafton, Erin K. Crane, Ramez N. Eskander, Sharad Ghamande, Whitney A. Spannuth Graybill, Thomas J. Herzog, Megan D. Indermaur, Veena S. John, Lisa M. Landrum, Peter Lim, Joseph A. Lucci, Michael McHale, Bradley J. Monk, Kathleen N. Moore, Robert Morris, David M. O’Malley, Thomas Reid, Debra L. Richardson, Peter G. Rose, Jennifer Scalici, Dan‐Arin Silasi, Krishnansu S. Tewari, Wenge Wang